A Major Setback for Germany's First Alzheimer's Drug: Lecanemab "Offers No Added Benefit"

Deutschlandfunk

Center

Factuality

Ownership

The Joint Federal Committee of Doctors, Health Insurances and Clinics sees no added value over previous forms of therapy in the Alzheimer's active substance "lecanemab" approved last year.

Tagesschau

Center

Factuality

Ownership

He was regarded as a source of hope - but doctors, health insurance companies and clinics do not see any proven added value in the Alzheimer active substance lecanemab. Nevertheless, the active substance is not useless.

n-tv.de

Lean Right

Factuality

Ownership

According to experts, Germany's first active substance in Alzheimer's disease is no better than conventional drugs. However, there is criticism of the evaluation. A decision on a second drug is still pending.

Zeit Online

Lean Left

Factuality

Ownership

Here you can find information on the topic "Health". Read now "Alzheimer-Mittel threatens the end – What's the next step?".

Welt

Lean Right

Factuality

Ownership

His approval was accompanied by great hopes, but apparently the new Alzheimer medicine Lecanemab has no added value. What does this mean for patients?

Berliner Morgenpost

Center

Factuality

Ownership

The Joint Federal Committee of Physicians, Health Insurance Funds and Hospitals sees no relevant additional benefit of the Alzheimer's drug Lecanemab.